
How Will Trump’s 50% Tariff on Copper, 200% Pharma Warning Affect India’s Export Sector?
July-9, 2025: Washington/New Delhi –
In a bold escalation of his protectionist trade agenda, US President Donald Trump on Tuesday announced a 50% tariff on copper imports and issued a stern warning of a 200% tariff on pharmaceutical products imported into the United States. These proposed measures are likely to have serious implications for India, which counts the US as a top trading partner in both copper and pharmaceuticals.
Also Read: Indian Stock Market Today: 8 Overnight Triggers from Trump’s Tariffs to Copper Surge
Speaking during a cabinet meeting, Trump declared:
“Today we’re doing copper. I believe the tariff on copper, we’re going to make it 50%.”
This move builds on previous duties placed on steel and aluminium and immediately triggered a surge in global copper prices. Trump confirmed the new tariffs will be effective by July-end or August 1.
Commerce Secretary Howard Lutnick later reinforced that tariffs would be rolled out aggressively and confirmed that studies into pharmaceuticals and semiconductors would be completed by month-end, potentially triggering more trade barriers.
Also Read: Could Mahindra’s New RevX Variants Supercharge the XUV 3XO Lineup?
Trump also issued a massive tariff warning on pharmaceuticals, saying:
“We’ll give manufacturers a year, maybe a year and a half to relocate production to the US. After that, we’re imposing a very high tariff—like 200%.”
This is particularly worrisome for India’s booming generic drug exports, which form the backbone of affordable healthcare in the US.
Trump didn’t hold back on geopolitics either. He reiterated a 10% blanket tariff threat on all BRICS member nations (Brazil, Russia, India, China, South Africa), calling the bloc “not a serious grouping” but one that’s challenging the US dollar’s dominance.
“It’s alright if you want to challenge the dollar. But you will have to pay the tariffs. I don’t think they want that,” Trump warned.
India exported $2 billion worth of copper and copper products globally in FY2024–25, with $360 million (17%) going to the US, its third-largest copper market. The new tariffs may squeeze this sector’s margins, though domestic demand could absorb the excess supply.
The bigger concern lies with India’s $9.8 billion pharma exports to the US, which account for 40% of India’s total drug exports. A 200% duty could cripple demand, undercutting the pricing advantage of Indian generics in the world’s largest pharmaceutical market.
India and the US are currently negotiating a mini trade agreement, and government officials say the August 1 deadline is critical. If the deal is inked in time, the proposed tariffs may not be enforced on Indian exports.
Donald Trump, US Tariffs, Copper Tariff, Pharmaceutical Exports, India-US Trade, BRICS Tariff, Trump Trade War, Indian Economy, Copper Exports, Pharma Industry, US-India Relations, Howard Lutnick, Generic Drugs, Mini Trade Deal
#TrumpTariffs #IndiaUSTrade #CopperTariff #PharmaExport #IndianEconomy #TradeWar #BRICS #Trump2025 #IndianPharma #GenericDrugs #MakeInIndia #USIndiaRelations #DonaldTrump
Just over two months after the premiere of his directorial debut, the Netflix series The…
Filmmaker Ram Gopal Varma (RGV) has once again stirred controversy by defending his descriptive comments…
Nine years after her terrifying 2016 Paris robbery, Kim Kardashian made a powerful statement of…
Bollywood icon Aishwarya Rai Bachchan captivated the audience at the Red Sea Film Festival 2025…
Amid concerns over air pollution stressing the body, the choice of dairy milk can play…
India's largest airline, IndiGo, is facing an unprecedented operational crisis, with over 1,000 flights cancelled…